Psychiatry | Page 13 of 61 | Links Medicus Content Curation & Alerts in Medicine

Living through the psychological consequences of COVID-19 pandemic: a systematic review of effective mitigating interventions.

16 Aug, 2022 | 13:43h | UTC

Living through the psychological consequences of COVID-19 pandemic: a systematic review of effective mitigating interventions – BMJ Open

RCT | Therapist-supported internet-delivered exposure and response prevention for children and adolescents with Tourette Syndrome.

16 Aug, 2022 | 13:18h | UTC

Therapist-Supported Internet-Delivered Exposure and Response Prevention for Children and Adolescents With Tourette Syndrome: A Randomized Clinical Trial – JAMA Network Open

Commentaries:

Internet-Based Cognitive Behavioral Therapy for Tourette Syndrome—Meaningfully Improving Access to Behavioral Therapy for Tics – JAMA Network Open

Online Exposure Therapy Improves Tic Symptoms in Youth – Psychiatric News Alert

Commentary on Twitter

In this RCT, 221 youths with #Tourette syndrome or chronic tic disorder received therapist-supported, internet-delivered exposure and response prevention (ERP) or education. Both groups improved over time, with no between-group differences in tic severity. https://t.co/YND2mgPn2Q

— JAMA Network Open (@JAMANetworkOpen) August 15, 2022

Cohort Study | Clinical correlates and outcomes of methamphetamine‐associated cardiovascular diseases in hospitalized patients.

16 Aug, 2022 | 13:03h | UTC

Clinical Correlates and Outcomes of Methamphetamine‐Associated Cardiovascular Diseases in Hospitalized Patients in California – Journal of the American Heart Association

Commentary: Methamphetamine use associated with cardiovascular disease in hospitalized patients – Physician’s Weekly

Commentary on Twitter

In one of the largest studies to date, Curran et al. found that #methamphetamine use is as big a risk for #heart #disease as alcohol and cocaine. @UCSFCardiology @LaraGroom #AHAJournals https://t.co/S82YLoVM7r pic.twitter.com/SkmxF3bG7d

— JAHA (@JAHA_AHA) August 12, 2022

Non-parenteral Ketamine for depression: a practical discussion on addiction potential and recommendations for judicious prescribing.

10 Aug, 2022 | 12:19h | UTC

Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing – CNS Drugs

RCT | Effectiveness of Varenicline and Cytisine for alcohol use reduction among people with HIV and substance use.

9 Aug, 2022 | 12:35h | UTC

Effectiveness of Varenicline and Cytisine for Alcohol Use Reduction Among People With HIV and Substance Use: A Randomized Clinical Trial – JAMA Network Open

Commentary: Varenicline and cytisine not more efficacious than nicotine to treat risky drinking and smoking, study says – News Medical / Vanderbilt University Medical Center

Commentary on Twitter

In this RCT, varenicline and cytisine were not more efficacious than nicotine to treat risky drinking and smoking among individuals with HIV; rates of behavior change for alcohol consumption and smoking were high in all treatment groups. #OrigInvestigation https://t.co/h8M6e5nOkf

— JAMA Network Open (@JAMANetworkOpen) August 5, 2022

Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study.

5 Aug, 2022 | 14:31h | UTC

Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study – The Lancet Psychiatry (link to abstract – $ for full-text)

Commentary on Twitter (thread – click for more)

cohort study in 1st-episode schizophrenia: The effectiveness of antipsychotics for relapse prevention decreased after the 2nd relapse. The aHR for rehospitalisation with AP use versus non-use increased from 0·42 to 0·78 after the 2nd relapse (p<0·0001) https://t.co/IBhDPNJJpe?

— P𝘧OL (@psychopharmacol) March 18, 2022

Review | Adults with intellectual disabilities and mental health disorders in primary care.

5 Aug, 2022 | 14:24h | UTC

Adults with intellectual disabilities and mental health disorders in primary care: a scoping review – British Journal of General Practice

Review | Recognizing and managing eating disorders in the emergency department.

5 Aug, 2022 | 14:22h | UTC

Recognising and managing eating disorders in the emergency department – Postgraduate Medical Journal

Cohort Study | The risk of opioid overdose is increased with concomitant use of oxycodone and selective serotonin reuptake inhibitors that are inhibitors of oxycodone metabolism.

4 Aug, 2022 | 14:27h | UTC

Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors – JAMA Network Open

Commentary from the author: Taking certain opioids while on commonly prescribed antidepressants may increase the risk of overdose – The Conversation

Commentary on Twitter

This cohort study found that concomitant use of oxycodone with potent CYP2D6-inhibiting serotonin reuptake inhibitors (SSRIs, eg. fluoxetine or paroxetine) is associated with an increased risk of overdose. https://t.co/Eol89RHWAu

— JAMA Network Open (@JAMANetworkOpen) February 24, 2022

Cohort Study | Bariatric surgery linked to doubling chance of marriage or divorce.

4 Aug, 2022 | 14:16h | UTC

News Release: Bariatric Surgery Linked to Doubling Chance of Marriage or Divorce – University of Pittsburgh

Original Study: Changes in Marital Status Following Roux-en-Y Gastric Bypass and Sleeve Gastrectomy: A US Multicenter Prospective Cohort Study – Annals of Surgery Open

Commentary: Spouse Getting Weight Loss Surgery? Your Marriage Might Be in Trouble – HealthDay

RCT | Transcranial direct current stimulation vs. sham for the treatment of inattention in adults with attention-deficit/hyperactivity disorder.

4 Aug, 2022 | 13:50h | UTC

Transcranial Direct Current Stimulation vs Sham for the Treatment of Inattention in Adults With Attention-Deficit/Hyperactivity Disorder: The TUNED Randomized Clinical Trial – JAMA Psychiatry (free for a limited period)

M-A | Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials.

3 Aug, 2022 | 14:31h | UTC

Response to acute monotherapy for major depressive disorder in randomized, placebo controlled trials submitted to the US Food and Drug Administration: individual participant data analysis – The BMJ

M-A | Prevalence of suicidal ideation and self-harm behaviors in children aged 12 years and younger.

1 Aug, 2022 | 12:01h | UTC

Prevalence of suicidal ideation and self-harm behaviours in children aged 12 years and younger: a systematic review and meta-analysis – The Lancet Psychiatry (link to abstract – $ for full-text)

Commentary on Twitter

*New* systematic review & meta-analysis estimates a prevalence of 7·5% for suicidal ideation, 2·2% for suicide planning, 1·4% for self-harm, 1·3% for suicide attempts, & 21·9% for non-suicidal self-injury in children aged ≤12 years

In @TheLancetPsych #childhoodsuicide https://t.co/wFbv6eKpNs

— The Lancet Child & Adolescent Health (@LancetChildAdol) July 28, 2022

RCT | Efficacy and safety of viloxazine extended-release capsules in adults with attention-deficit/hyperactivity disorder.

1 Aug, 2022 | 11:57h | UTC

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder – CNS Drugs

A large observational study suggests long-acting injectable antipsychotics are associated with better outcomes than oral antipsychotics in people with schizophrenia.

29 Jul, 2022 | 12:25h | UTC

Association of Long-Acting Injectable Antipsychotics and Oral Antipsychotics With Disease Relapse, Health Care Use, and Adverse Events Among People With Schizophrenia – JAMA Network Open

Invited Commentary: Improving Outcomes in Schizophrenia—A Case for Initiation of Long-Acting Antipsychotics in Early-Phase Illness – JAMA Network Open

Long-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia – The Journal of Clinical Psychiatry (link to abstract – $ for full-text)

Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis – The Lancet (link to abstract – $ for full-text)

Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies – The Lancet Psychiatry (link to abstract – $ for full-text)

Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial – JAMA Psychiatry

Commentary on Twitter

This case series of people with schizophrenia found long-acting injectable antipsychotics were associated with less disease relapse and hospitalization vs oral antipsychotics, w/o an increased risk of adverse events. @Esther_CSMPRHKU @HKUPharm @hkumed https://t.co/ZiPkV4lSk0

— JAMA Network Open (@JAMANetworkOpen) July 28, 2022

M-A | Socioeconomic indicators of treatment prognosis for adults with depression.

29 Jul, 2022 | 12:17h | UTC

Socioeconomic Indicators of Treatment Prognosis for Adults With Depression: A Systematic Review and Individual Patient Data Meta-analysis – JAMA Psychiatry

News Release: People without jobs or secure housing have worse outcomes when treated for depression – University College London

Commentary: Unemployment and insecure housing are linked to less successful treatment for depression – National Institute for Health and Care Research

Commentary on Twitter

Socioeconomic disadvantage in employment and housing is associated with considerably worse outcomes in #depression, regardless of treatment type and after adjusting for clinical prognostic factors. https://t.co/bVTQv5zx8C

— JAMA Psychiatry (@JAMAPsych) May 6, 2022